ERBB2 and non-small cell lung carcinoma: Furmonertinib maybe one effective and economical treatment for NSCLC patients harboring HER2 mutations with minor side effects.<h4>Case description</h4>We present a case report of a 49-year-old female diagnosed with stage IV lung adenocarcinoma who complained of irritating dry cough symptoms followed by chest tightness.